Robert A. Figlin, MD, on the Potential Importance of Adjuvant IO in Bladder Cancer

Article

Robert A. Figlin, MD, discusses the potential role of adjuvant immunotherapy for patients with bladder cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Robert A. Figlin, MD, professor of Biomedical Sciences and Medicine, Steven Spielberg Family Chair in Hematology-Oncology, and deputy director of Cedars-Sinai Cancer, to highlight the potential importance of adjuvant immunotherapy in bladder cancer. As previous research has identified significant benefit with this modality, Figlin emphasizes the importance of discovering the best role for immunotherapy in this patient population.

Transcript:

Concomitant with ASCO was a recent New England Journal of Medicine article talking about immunotherapy in the invasive bladder cancer population, [which demonsted] a substantial and significant benefit [to therapy]. We should start to think about adjuvant immunotherapy for bladder cancer. [This would be] primarily diseases of the bladder, not necessarily the ureter or the kidney. As we continue to expand and search for appropriate roles for immunotherapy, we should not forget other diseases like bladder cancer in that setting.

Reference

Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114. doi:10.1056/NEJMoa2034442

Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content